Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Selects New CEO | Contract Pharma
Breaking News, Promotions & Moves

Sanofi Selects New CEO

Brandicourt succeeds ousted Viehbacher

Olivier Brandicourt has been appointed chief executive officer of Sanofi, effective April 2. Dr. Brandicourt succeeds Chris Viehbacher who was fired last October amidst whistleblower lawsuit claims that the company was involved in a kickback scheme directed through consultants for diabetes drug sales in the U.S.
 
Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as chairman of the board of management of Bayer HealthCare AG and member of the executive council at Bayer AG. Previously, he held positions of increasing responsibility at global pharmaceutical groups, including Parke-Davis/Warner-Lambert and Pfizer. Dr. Brandicourt also served as a member of Pfizer’s global executive leadership team from 2010 to 2013. 
 
Serge Weinberg, chairman of the board of directors, Sanofi said, “Sanofi undertook a rigorous selection process to identify the right person to lead Sanofi forward at an important time for our company. I am very pleased that Olivier Brandicourt will be the next chief executive officer of Sanofi. Olivier Brandicourt’s strong experience combined with his international profile, deep knowledge of U.S. and emerging healthcare markets, and his capability to unite teams will provide new dynamism to Sanofi’s strategy of diversification and innovation.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters